Demonstrate significant progress toward leadership in Systemic Mastocytosis (SM), including mid-year Part 1 results from…
Surface Oncology initiates clinical trial with antibody discovered using Vaccinex’s ActivMAb® Antibody Discovery Platform ROCHESTER,…
REDWOOD CITY, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Nasdaq: BMEA), a…
– ARCALYST® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and…
Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533…
CVN766 was well tolerated with no serious adverse events CVN766, which has >1000-fold selectivity for…
Russel Skibsted 2MB Russell Skibsted, CFO of Alimera Sciences Russell Skibstead Hi-Res Russell Skibsted, CFO…
SAN FRANCISCO, Jan. 09, 2023 (GLOBE NEWSWIRE) — Rezo Therapeutics, a biotechnology company pioneering the…
-Clinical trial is being conducted at St. James’s University Hospital, United Kingdom, in collaboration with…
PROCEPT BioRobotics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 28,…
SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences,…
NEW PDUFA DATE OF MAY 19, 2023 PITTSBURGH, Jan. 09, 2023 (GLOBE NEWSWIRE) — Krystal…
Approximately $2.9 Million from Sale of Its New Jersey State Net Operating Losses (“NOLs”), Plus…
MRT-2359 received Fast Track designation from the FDA for the treatment of patients with previously…
Multiyear Development and Support Agreement Lays the Foundation for the Realization of an Advanced Software…
Lonza to support the development and manufacturing of CTIM-76, Context’s CLDN6 x CD3 bispecific antibody…
GreenLight GreenLight’s mRNA design, formulation and manufacturing expertise is currently applied to research and develop…
—ORLADEYO preliminary 2022 full year net revenue of $251.6 million (+105 percent y-o-y)— —ORLADEYO net…
Independent data monitoring committee recommends that the company’s Phase 3 trial evaluating IO102-IO103 in combination…
—Company also expanding its discovery platform in complement-mediated diseases, including potent, selective, oral molecules targeting…